leadf
logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma CEO details new US Traumakine study and updates on Clevegen expansion plans

Faron Pharmaceuticals' (LON:FARN) Dr Markku Jalkanen speaks to Proactive London's Andrew Scott following a successful virtual R&D day this week.

He also reports on the continued progress for two of its clinical stage programmes, Clevegen and Traumakine, including the just-announced HIBISCUS ( Human Interferon Beta In Severe CoronavirUS) trial which will focus on intensive care patients with ARDS caused by viral infection such as coronavirus and influenza.

Quick facts: Faron Pharmaceuticals Ltd

Price: 290 GBX

AIM:FARN
Market: AIM
Market Cap: £135.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Faron Pharmaceuticals' explains the significance of latest WHO solidarity...

Faron Pharmaceuticals' (LON:FARN) Markku Jalkanen explains the context and meaning behind the latest results from a study that showed little impact from interferon Beta-1a injected under the skin in halting coronavirus-related deaths. The World Health Organisation's (WHO) Solidarity trial...

12 hours, 44 minutes ago

2 min read